

Bilenker Joshua H.  
Form 4  
July 11, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Bilenker Joshua H.

(Last) (First) (Middle)

C/O LOXO ONCOLOGY, INC., 281  
TRESSER BOULEVARD, 9TH  
FLOOR

(Street)

STAMFORD, CT 06901

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
Loxo Oncology, Inc. [LOXO]

3. Date of Earliest Transaction  
(Month/Day/Year)

07/09/2018

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)  
President & CEO

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/09/2018		M <sup>(1)</sup>	7,500	A \$ 1.184	142,907	D
Common Stock	07/09/2018		S <sup>(1)</sup>	900 <sup>(2)</sup>	D \$ 184.8698	142,007	D
Common Stock	07/09/2018		S <sup>(1)</sup>	1,500 <sup>(2)</sup>	D \$ 186.3849	140,507	D
Common Stock	07/09/2018		S <sup>(1)</sup>	3,698 <sup>(2)</sup>	D \$ 187.3871	136,809	D

Edgar Filing: Bilenker Joshua H. - Form 4

					(5)		
Common Stock	07/09/2018	S <sup>(1)</sup>	802 <sup>(2)</sup>	D	\$ 188.2849 <sup>(6)</sup>	136,007	D
Common Stock	07/09/2018	S <sup>(1)</sup>	300 <sup>(2)</sup>	D	\$ 189.43 <sup>(7)</sup>	135,707	D
Common Stock	07/09/2018	S <sup>(1)</sup>	300 <sup>(2)</sup>	D	\$ 191.6333 <sup>(8)</sup>	135,407	D
Common Stock	07/10/2018	M <sup>(1)</sup>	7,500	A	\$ 1.184	142,907	D
Common Stock	07/10/2018	S <sup>(1)</sup>	2,200 <sup>(2)</sup>	D	\$ 178.1923 <sup>(9)</sup>	140,707	D
Common Stock	07/10/2018	S <sup>(1)</sup>	2,200 <sup>(2)</sup>	D	\$ 179.0809 <sup>(10)</sup>	138,507	D
Common Stock	07/10/2018	S <sup>(1)</sup>	1,000 <sup>(2)</sup>	D	\$ 180.081 <sup>(11)</sup>	137,507	D
Common Stock	07/10/2018	S <sup>(1)</sup>	1,300 <sup>(2)</sup>	D	\$ 181.2077 <sup>(12)</sup>	136,207	D
Common Stock	07/10/2018	S <sup>(1)</sup>	800 <sup>(2)</sup>	D	\$ 182.8388 <sup>(13)</sup>	135,407	D

Common Stock						30,000	I
--------------	--	--	--	--	--	--------	---

By Joshua  
H Bilenker,  
tee Joshua  
H Bilenker  
2018  
GRAT,  
dated  
06/20/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D S
---------------------------------------	---------------------------------	---	---	---------------------------	--	--	---	--------------

# Edgar Filing: Bilenker Joshua H. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 1.184	07/09/2018	M <sup>(1)</sup>	7,500					<sup>(14)</sup>	11/14/2023	Common Stock	7,500
Employee Stock Option (right to buy)	\$ 1.184	07/10/2018	M <sup>(1)</sup>	7,500					<sup>(14)</sup>	11/14/2023	Common Stock	7,500

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bilenker Joshua H. C/O LOXO ONCOLOGY, INC. 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901	X		President & CEO	

## Signatures

/s/ Jennifer Burstein, by power of attorney 07/11/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- (2) Represents the aggregate of sales effected on the same day at different prices.  
Represents the weighted average sales price per share. The shares sold at prices ranging from \$184.72 to \$185.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (3) Represents the weighted average sales price per share. The shares sold at prices ranging from \$185.73 to \$186.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (4) Represents the weighted average sales price per share. The shares sold at prices ranging from \$185.73 to \$186.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (5)

## Edgar Filing: Bilenker Joshua H. - Form 4

Represents the weighted average sales price per share. The shares sold at prices ranging from \$186.94 to \$187.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (6) Represents the weighted average sales price per share. The shares sold at prices ranging from \$188.04 to \$188.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (7) Represents the weighted average sales price per share. The shares sold at prices ranging from \$189.12 to \$190.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (8) Represents the weighted average sales price per share. The shares sold at prices ranging from \$191.63 to \$191.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (9) Represents the weighted average sales price per share. The shares sold at prices ranging from \$177.57 to \$178.52 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (10) Represents the weighted average sales price per share. The shares sold at prices ranging from \$178.60 to \$179.49 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (11) Represents the weighted average sales price per share. The shares sold at prices ranging from \$179.60 to \$180.54 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (12) Represents the weighted average sales price per share. The shares sold at prices ranging from \$180.93 to \$181.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (13) Represents the weighted average sales price per share. The shares sold at prices ranging from \$182.50 to \$183.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (14) The options have fully vested and are immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.